ONWARD

24/09/2025

Reminder: Webinar is Tomorrow!

Join us tomorrow, September 25 at 12:00 PM ET, co-hosted with the Christopher & Dana Reeve Foundation, and learn more about Empower BP, a global pivotal study to evaluate the ARC-IM System, an implantable neurostimulation therapy for blood pressure instability after spinal cord injury ( ). Hear directly from ONWARD, study investigators, and SCI community members who have participated in prior ARC-IM studies.

👉 Register now: https://bit.ly/4mkietd

More info: https://www.clinicaltrials.gov/study/NCT07147296

We look forward to seeing you there!

19/09/2025

We recently announced that the US FDA has approved an investigational device exemption (IDE) for the ONWARD ARC-IM System. This approval allows the initiation of Empower BP, a global pivotal study to assess the safety and efficacy of the implantable neurostimulation technology in addressing blood pressure instability following spinal cord injury.

Many people living with experience symptomatic blood pressure instability, where disruptions in the autonomic nervous system cause blood pressure to fluctuate between abnormally low and high levels. This under-appreciated and unmet need has a significant impact on both cardiovascular health and quality of life.

Join our webinar in collaboration with the Christopher & Dana Reeve Foundation to learn more about the global Empower BP pivotal study. It will feature speakers from ONWARD, study principal investigators, and SCI community members who participated in past studies investigating ARC-IM Therapy to treat symptomatic blood pressure instability.

When: September 25 at 12:00 PM ET
Register here: https://us02web.zoom.us/webinar/register/8317580514853/WN_bUdVrPSvQgmXjUwYDJf7sw #/registration

We look forward to engaging with you during this session!

For more details about the study, please visit: https://www.clinicaltrials.gov/study/NCT07147296

ARC-IM® is investigational and not available for commercial use. The safety and effectiveness of this therapy are currently being evaluated in clinical studies and are under review by the US Food and Drug Administration (FDA). Limited by United States law to investigational use.

18/09/2025

We are proud to announce the simultaneous publications of two articles in the highly respected academic journals Nature and Nature Medicine. They highlight advances in blood pressure regulation after spinal cord injury (SCI) and add to the compelling body of scientific and clinical evidence supporting the investigational ARC-IM® System, our implanted neuromodulation platform designed to deliver targeted and personalized spinal cord stimulation.

Both publications support our commitment to introducing therapies that address critical autonomic functions impacted by . These results demonstrate the potential of ARC-IM Therapy for managing blood pressure instability in advance of the planned initiation of the Empower BP global pivotal study later this year.

Read the full press release: https://lnkd.in/eahW9SSt
Nature article: https://lnkd.in/gvvJ2Mvi
Nature Medicine article: https://lnkd.in/gMf8YAyj



ARC-IM® is investigational and not available for commercial use. To stay informed about ONWARD’s technologies, research studies, and future availability in your area, please complete the webform linked in the comments below.

08/09/2025

We are pleased to announce that we have received CE Mark certification for the ARC-EX® System, enabling commercialization of our breakthrough spinal cord stimulation system in the European Union and certain other countries. This certification enables us to promote its use to improve hand strength and sensation after spinal cord injury, both in the clinic and at home.

The ARC-EX Therapy opens new doors for the European community, offering opportunities for recovery and care that were previously unavailable. It gives us great satisfaction to bring this important new therapeutic option to people living with paralysis in Europe.

Read the full press release: https://ir.onwd.com/static-files/a535cfdb-3cdf-4e12-b0fb-a22805640da0

To stay informed about ONWARD’s research studies, technologies, and the availability of therapies in your area, please complete the webform linked in the comments below.



ARC-EX Indication for Use (EU): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic and with take-home exercises in the home to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic (>1 year post-injury), non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive).

03/09/2025

We are heading to Philadelphia for the 2025 ASCIP Annual Meeting!

Organized by the Academy of Spinal Cord Injury Professionals (ASCIP), this conference is an opportunity for experts to connect, exchange ideas, and support new research. If you’re attending the conference, come visit us at Booth 201 to meet our team and learn about the ARC-EX® System, the first and only FDA-cleared technology to help improve hand strength and sensation in people with spinal cord injury.

We look forward to seeing you there!



ARC-EX Indication for Use (US): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old who present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive).

23/08/2025

We are proud to return to the Paralyzed Veterans of America(PVA) Healthcare Summit + Expo 2025, supporting this important event for the , and communities as a Gold Sponsor.

Held from August 24-27 in New Orleans, the summit offers a unique opportunity to learn, share, and engage with clinicians and professionals across multiple disciplines, fostering an integrated approach to care.

If you’re attending the conference, mark your calendar: ONWARD will host an expert session and live Q&A on August 26 at 12:00 PM with Dr. Candace Tefertiller, PT, DPT, PhD, NCS, Dr. Jenny Kiratli, PhD, and Sean Sciara. We will discuss the early real-world experience with the ARC-EX® System, the first and only FDA-cleared technology indicated to improve hand strength and sensation after spinal cord injury.

Stop by Booth 303 in the conference hall to say hi to our team and learn more about our latest technologies. We look forward to connecting with you there!



ARC-EX Indication for Use (US): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive).

18/08/2025

We are pleased to announce that the US Food and Drug Administration has approved an investigational device exemption (IDE) for the ARC-IM® System, our implanted neuromodulation platform designed to deliver targeted and personalized spinal cord stimulation.

With this IDE approval, we can initiate the Empower BP global pivotal study to assess the safety and efficacy of the implantable ARC-IM System to address blood pressure instability after spinal cord injury. The study is expected to involve approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe, with first patient enrollment anticipated before the end of the year.

This is an important milestone for ONWARD and the community. Blood pressure instability is a major recovery target after spinal cord injury. It affects more than 50% of people with SCI, impacting neurological recovery, cardiovascular health, and quality of life.

Read the full press release: https://ir.onwd.com/news-events



ARC-IM® is investigational and not available for commercial use. To stay informed about ONWARD’s research studies, technologies, and the availability of therapies in your area, please complete the webform linked in the comments below.

13/08/2025

“There is a quiet dignity in needing less help.”

That is how Jessie Owen, an ARC-EX® Therapy trial participant, reflects on her journey with the device and her renewed confidence to complete daily tasks and live life independently. Our groundbreaking ARC-EX System is the first and only US FDA-cleared technology indicated to improve hand sensation and strength after a spinal cord injury.

We were proud to see Jessie’s experience with it recognized on Fast Company's list of World Changing Ideas 2025. 🌎💡

Fast Company’s annual World Changing Ideas Awards honor the businesses and organizations that are developing creative solutions to the most pressing issues of our time. Thank you for highlighting stories like Jessie’s as we advance our mission to bring breakthrough therapies to people with and other movement disabilities.

Read more about the World Changing Ideas 2025 at the link in our comments.



ARC-EX Indication for Use (US): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive).

05/08/2025

CORE (Center of Recovery & Exercise) is one of the activity-based training centers in the US to be equipped with our groundbreaking ARC-EX® System.

At CORE, people living with paralysis from neurological conditions can challenge their diagnoses thanks to state-of-the-art technology and neurorehabilitation techniques. Now, their Florida-based team is fully trained on using our ARC-EX Therapy to improve hand strength and sensation after a spinal cord injury.

Huge thanks to the team at CORE for your engagement during our training sessions, and for the critical work you’re doing to bring hope and a space for people to reach their potential.



To stay informed about our technologies, research studies, and the availability of therapies in your area, please complete the form linked in the comments.

ARC-EX Indication for Use (US): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive).

22/07/2025

We are pleased to share the story about Walk The Line - Recovery Therapy, which is one of the first US clinics to use our ARC-EX® System to improve hand sensation and strength after a spinal cord injury.

Erica Coulston, President at Walk The Line, had this to say about her experience:

“It gives a glimmer of what could be, and that is so exciting. It makes you feel like you can do anything, and that is what we want.”

📺 Watch the Fox 2 Detroit segment here: https://www.fox2detroit.com/video/1675875



To be kept informed about the Company's technologies, research studies, and the availability of therapies in your area, please complete the form linked in the comments.

ARC-EX Indication for Use (US): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive).

16/07/2025

📣 We'll be there! ONWARD is heading to the 2025 National Veterans Wheelchair Games, the largest annual wheelchair sports and rehabilitation event for US military veterans.

Held on July 17-22 in Minneapolis, Minnesota, the event is organized by U.S. Department of Veterans Affairs and Paralyzed Veterans of America. It’s an exceptional opportunity to celebrate strength, resilience, and athletic spirit. From basketball to pickleball, the games are open to US veterans with spinal cord injuries, amputations, multiple sclerosis, or other central neurological conditions requiring a wheelchair. 🏆

We’re proud to support this powerful platform and its mission to foster wider respect and opportunities for all people living with disabilities.

Heading to the games? Come see us at booth #526 to discover how our groundbreaking ARC-EX® System is helping shape the future of spinal cord injury.



To stay informed about our technologies, research studies, and the availability of therapies in your area, please complete the form linked in the comments.

ARC-EX Indication for Use (US): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive).

11/06/2025

We're honored to be recognized as a company striving to make the world a better place on Fast Company’s 2025 World Changing Ideas list! 🌎💡

Fast Company World Changing Ideas Awards celebrate businesses and organizations developing creative solutions to the world's most pressing challenges. We’re thankful that our groundbreaking ARC-EX® System, the first and only FDA-cleared technology indicated to improve hand strength and sensation in people with chronic spinal cord injury, has been recognized for its potential to transform lives.

This honor belongs to our passionate team, dedicated partners, and everyone in the broader spinal cord injury community who inspire us daily. Together, we're demonstrating that pioneering medical technology can deliver life-changing impact for people with spinal cord injury and other movement disabilities.

Thank you, Fast Company, for shining a light on solutions that matter.

https://www.fastcompany.com/91336535/onward-medical-world-changing-ideas-2025

ARC-EX temporarily attaches electrodes to the skin to stimulate sensory nerves in the spine. It’s a winner in Fast Company’s 2025 World Changing Ideas Awards.